Comparison of the efficacy of erlotinib/Tarceva and gefitinib in the treatment of lung adenocarcinoma

In the treatment of non-small cell lung cancer (NSCLC), especially lung adenocarcinoma, the emergence of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has changed the traditional treatment landscape. Erlotinib(Erlotinib) and gefitinib (Iressa), as the first-generation EGFR-TKIs, both inhibit tumor cell proliferation and delay disease progression by blocking the EGFR signaling pathway. The two are highly similar in pharmacological mechanisms, but there are certain differences in efficacy, side effect characteristics, clinical positioning and accessibility. Therefore, they are often compared clinically in the precision treatment of lung adenocarcinoma.

From the perspective of efficacy, both have demonstrated a high objective response rate and prolonged progression-free survival in the EGFR-sensitive mutation population (mainly exon 19 deletion and exon 21 L858R mutation). Multiple overseas controlled studies have shown that there is little difference in overall efficacy between erlotinib and gefitinib, and both are significantly better than chemotherapy alone. The benefits are particularly prominent in Asian non-smoking women with lung adenocarcinoma. However, some clinical experiences believe that erlotinib has a more obvious allergic reaction to skin rash in some patients, while gefitinib has a slightly higher incidence of abnormal liver function in some patients. Therefore, the patient's tolerance and co-existing diseases will be considered in individualized selection.

In terms of pharmacokinetics, the absorption rate of erlotinib is closely related to diet and must be taken on an empty stomach, otherwise it may cause fluctuations in blood concentration. Gefitinib is relatively less affected by food and has greater flexibility in medication time, which is also a major difference between the two in terms of medication convenience. In addition, the interaction between erlotinib and smoking is more significant. Smoking can reduce its blood concentration and thus affect its efficacy. Therefore, doctors usually recommend that patients strictly quit smoking during the medication.

In terms of resistance mechanisms, erlotinib and gefitinib are both first-generation EGFR-TKIs.Acquired resistance is prone to occur after long-term use. The most common mechanism is the EGFR T790M mutation. With the emergence of a new generation of EGFR inhibitors such as osimertinib, treatment strategies for drug resistance have changed, but erlotinib and gefitinib are still widely used in clinical practice as first-line treatments, especially in some countries and regions with good medical insurance coverage, and are still the first choice for patients.

From the perspective of price and accessibility, gefitinib is one of the first EGFR-TKIs to be launched in China and enter the medical insurance market. Therefore, it has higher clinical penetration rate, relatively low price, and lighter patient burden. Erlotinib has also been included in medical insurance in China, but its market positioning is slightly higher than that of gefitinib. In the international market, especially in India and Bangladesh, generic drugs of both are already on the market, with little price difference and good patient accessibility.

Taken together, erlotinib and gefitinib are equally effective in the treatment of lung adenocarcinoma. The main differences are reflected in pharmacokinetic characteristics, side effect spectrum, price accessibility, and patient tolerance. For clinicians, the choice of which drug to choose is based more on the patient's individual circumstances, including mutation type, previous treatment history, financial status, and lifestyle habits. For patients, both are proven and effective options. Proper selection and regular monitoring during treatment can maximize benefits.

Reference materials:https://en.wikipedia.org/wiki/Erlotinib